Boston Scientific cancels $230M stent deal after regulators erect barriers to acquisition

The Federal Trade Commission said Boston Scientific took the action in response to investigations by its staff and overseas enforcement partners.

By Nick Paul Taylor • May 26, 2023

Illumina chair loses to Icahn pick as proxy battle ends

The decision to replace board Chair John Thompson could change the company’s course as it decides whether to divest liquid biopsy company Grail.

By Elise Reuter • Updated May 25, 2023

Medtronic posts profit, sales growth in Q4, agrees to buy Korean diabetes patch maker

The company is “confident in delivering durable revenue growth in the year ahead” amid continued improvements in procedure volumes.

By Peter Green • May 25, 2023

Medtronic agrees to buy Korean insulin patch pump maker for $738m to boost diabetes business

The tubeless, disposable insulin patch made by EOFlow will be integrated into Medtronic’s MiniMed 780G system.

By Elise Reuter • May 25, 2023

A Boston Scientific purchase of Shockwave could be transformative — but at what price?

Boston Scientific has used “tuck-in” acquisitions to boost growth in the past. Some analysts say it should stay the course amid a report the company may make a bid.

By Susan Kelly • May 19, 2023

Icahn bolstered by another proxy advisor in battle with Illumina

The DNA-sequencing company defended its board chair, John Thompson, and drew attention to a new disclosure that Icahn’s firm is being investigated by the U.S. attorney for the Southern District of New York.

By Susan Kelly • Updated May 15, 2023

Baxter to sell biopharma solutions unit for $4.25B to private equity

The company said it plans to use the proceeds of the sale to pay down its debt.

By Elise Reuter • May 8, 2023

Globus shareholders approve share issuance for $3.1B NuVasive purchase

NuVasive’s shareholders also OK’d the merger agreement, bringing the deal a step closer to closing.

By Elise Reuter • April 28, 2023

Quest Diagnostics to pay $450M to buy liquid biopsy cancer test developer as Q1 revenue drops

The laboratory services provider said patients are returning to the healthcare system for routine care, but COVID testing has plummeted as the pandemic winds down.

By Susan Kelly • April 27, 2023

Boston Scientific considering purchase of Shockwave Medical: Bloomberg

The acquisition, which would be Boston Scientific’s largest in recent history, would add to the company’s cardiac portfolio.

By Elise Reuter • April 21, 2023

Alphatec buys robotic spine navigation system for $55M

The spine surgery specialist expects the robotic platform to begin generating revenue in 2025.

By Susan Kelly • Updated April 21, 2023

Illumina slaps back at Icahn’s board nominees, opens proxy collection

The fight continues as Illumina aims to block Icahn’s nominees from ousting its CEO and board chair.

By Peter Green • April 20, 2023

Medtech buyouts by private equity in Q4 shed light on deal-making trends in 2023: report

Medtech companies are continuing to spin off assets to realign portfolios, creating opportunities for private equity firms to buy businesses and exit existing investments.

By Nick Paul Taylor • April 11, 2023

Bioventus CEO departs after CartiHeal acquisition unravels

Ken Reali was asked to leave after a deal to buy CartiHeal fell apart. Bioventus’ share price has fallen more than 90% in the past two years. 

By Susan Kelly • April 6, 2023

Icahn ramps up rhetoric on Illumina after FTC orders Grail sale

In a letter to Illumina shareholders, Icahn says the two companies “should be separated immediately” to protect “long term growth prospects.”

By Peter Green • April 5, 2023

Bain acquires Olympus life sciences unit for $3.1B

The company aims to expand its position as a workflow solution provider in life science and industrial markets.

By Susan Kelly • April 3, 2023

Illumina urges shareholders to reject Icahn board nominees

The DNA-sequencing company says Icahn’s board nominees don’t understand its business or the regulatory process.

By Susan Kelly • March 31, 2023

ICU Medical challenges GE HealthCare for Medtronic units valued at $8B: report

Medtronic wants to spin off or sell the two units to focus on faster-growing parts of its business and is talking to potential buyers.

By Nick Paul Taylor • March 30, 2023

SonderMind acquires technology from Mindstrong ahead of digital health startup’s shutdown

Mindstrong’s collapse comes in a turbulent period for the digital health sector.

By Nick Paul Taylor • March 23, 2023

NuVasive shareholders expected to ‘begrudgingly’ back Globus’ $3.1B takeover amid lack of other bidders

Analysts said “none of the other major strategic players were in a position to bid on NuVasive — either because they were not interested or were financially tied up in other areas.”

By Nick Paul Taylor • March 22, 2023

Illumina, facing Icahn challenge, ‘moving quickly’ on resolution for Grail

The DNA-sequencing company said the activist investor hasn’t offered any better solutions for satisfying regulators’ concerns about the acquisition.

By Susan Kelly • March 20, 2023

Getinge buys sterilization firm Ultra Clean Systems for $16M

The Sweden-based company, which already partnered with Ultra Clean as a distributor, said the deal will “significantly expand” its offerings to sterile reprocessing departments.

By Elise Reuter • March 15, 2023

Illumina shares jump 17% after Icahn launches proxy fight

The activist investor said his board nominees would work to prevent Illumina from “sinking further into the quicksand” in a battle with regulators over the Grail acquisition.

By Susan Kelly • Updated March 14, 2023

Olympus agrees to $370M gastrointestinal stent takeover as medtech M&A rebound continues

The deal for Korea-based Taewoong, which makes stents used to help clear blockages, supports Olympus’ plan to expand in the GI market.

By Nick Paul Taylor • Feb. 28, 2023

Globus’ full-year sales top $1B as analysts continue to question wisdom of NuVasive takeover

Analysts raised concerns about Globus’ planned $3.1 billion takeover of spine specialist NuVasive, asking about the company’s “flexibility and willingness to close the deal.” 

By Nick Paul Taylor • Feb. 23, 2023